Hemispherx BioPharma, Inc (NYSEMKT:HEB) woke up to a nice 10% pop in the value of their shares, after the drug maker commenced full data …
Hemispherx BioPharma, Inc (NYSEMKT:HEB) announced that on Thursday, August 3, 2017 it participated in a meeting in Toronto, Canada with Canadian advocates for …
Hemispherx BioPharma, Inc (NYSE MKT:HEB) said today that a new study led by a team of researchers from Stanford University may provide the …
Hemispherx BioPharma, Inc (NYSEMKT:HEB) announced that 12 pancreatic patients are currently undergoing treatment with single-agent Ampligen immuno-oncology therapy in an Early Access Program …
Hemispherx BioPharma, Inc (NYSEMKT:HEB) announced today that it has met a major milestone, the commencement of sales of recently manufactured Ampligen in international …
This morning, Hemispherx BioPharma, Inc (NYSEMKT:HEB) announced that it has entered into definitive agreements with several institutional investors for an offering of shares …
Hemispherx BioPharma, Inc (NYSEMKT:HEB) announced that an order of newly manufactured rintatolimod (Ampligen®) for sale utilizing the Early Access Program (EAP) in Europe …
Hemispherx BioPharma, Inc (NYSEMKT:HEB) announced that the rintatolimod European early access program (EAP) designed to enable access of the compound to ME/CFS patients …
Hemispherx BioPharma, Inc (NYSE:HEB) announced that a retrospective analysis of the AMP-516 Phase III trial of Ampligen® in patients with chronic fatigue syndrome/myalgic …
Hemispherx BioPharma, Inc (NYSEMKT:HEB) announced that it has completed its technology transfer of the Ampligen® manufacturing processes to Avrio Biopharmaceuticals (“Avrio”). The transfer …
